Wednesday, May 13, 2020 11:26:49 AM
Yes, indeed, this new report from neurologists at Massachusetts General Hospital (associated with Harvard) provide further evidence that blarcamesine (Anavex 2-73) is able to either stop the progression of Alzheimer’s disease, or even reverse or prevent it.
For those who missed it, read the report closely, here:
https://www.massgeneral.org/news/press-release/researchers-link-high-calcium-levels-in-mitochondria-to-neuronal-death-in-alzheimers
When I first encountered Anavex science, several years ago, I examined all of the published research articles on (then) “Anavex 2-73,” (now, “blarcamesine”). Therapeutic results for a number of central nervous system (CNS) disorders — all in murines, lab rodents — were quite remarkable; yielding results that conventional drugs or therapies could not. Too good to be true; at least if ever tried in real humans. At the time, it was difficult to explain how this rather simple molecule could have so many good, “downstream” health-restorative effects.
I am a biologist (retired advanced placement biology teacher; presently a researcher leading a university team using ecological processes to solve a major environmental problem; working with a major federal grant just awarded to us). I understand cellular physiology and biochemical processes. It was clear to me (and others) that the Anavex sigma-1 receptor antagonist, Anavex 2-73, after binding to and activating the sigma-1 receptor protein, allowed that protein then to function normally.
One function (too complicated to describe in less than a dozen paragraphs, with illustrative graphics) is to support the function of the endoplasmic reticula, tiny organelles that properly fold proteins into functioning enzymes. Those properly-folded enzymes mediate virtually all of the hundreds of chemical reactions in cells. But if any of those enzyme proteins are mis-folded, essential reactions are compromised. Pathology results.
So, restoration or support of proper protein folding by Anavex 2-73 in endoplasmic reticula was a plausible mechanism of action (MOA) explaining the positive therapeutic results. Simply, Anavex 2-73 caused proteins to be properly folded into fully-functioning enzymes. Some of those enzymes properly reduce and destroy cellular wastes, such as the amyloids that pathogenically accumulate to cause Alzheimer’s. That’s what I’ll call the Anavex MOA No. 1.
But now, with this new research, there might be an Anavex MOA No. 2; the drug’s facilitation of proper calcium ion transport. This needs to be affirmed in transgenic lab rodents with the human genes for Alzheimer’s. Simply replicate the new study, but this time add some blarcamesine to the rodents’ drinking water; then see what happens, grossly (observed behaviors), and biochemically. I’d bet a dozen or so of my AVXL shares that normalized calcium modulation will result. The new study shows that with this, severity or occurrence of Alzheimer’s could be reduced or prevented.
Altogether, more solid evidence that the Anavex molecule is not too good to be true. It’s multiple, positive therapeutic outcomes are ever more firmly based and affirmed by its unique biochemistry.
And Anavex Life Sciences Corp has another proprietary analog, Anavex 3-71, for which murine studies indicate even stronger and wider therapeutic efficacies.
The means by which these occur are no longer so mysterious.
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM